Balanced Wealth Group LLC Raises Stock Holdings in AbbVie Inc. $ABBV

Balanced Wealth Group LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 23.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,609 shares of the company’s stock after buying an additional 691 shares during the quarter. Balanced Wealth Group LLC’s holdings in AbbVie were worth $682,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Norges Bank purchased a new position in AbbVie during the second quarter valued at $4,288,200,000. Nuveen LLC purchased a new position in AbbVie in the 1st quarter valued at about $1,819,154,000. Laurel Wealth Advisors LLC boosted its holdings in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in AbbVie by 550.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after buying an additional 3,666,521 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of AbbVie by 31.6% during the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.4%

Shares of ABBV stock opened at $226.72 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company’s 50-day moving average price is $227.71 and its 200-day moving average price is $206.67. The stock has a market cap of $400.69 billion, a price-to-earnings ratio of 107.96, a PEG ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABBV shares. Morgan Stanley lifted their price target on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research note on Tuesday, November 4th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Finally, Bank of America boosted their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.